Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.59 USD
−16.48 M USD
0.00 USD
26.49 M
About FibroBiologics, Inc.
Sector
Industry
CEO
Peter O'Heeron
Website
Headquarters
Houston
Founded
2021
FIGI
BBG01K4MB400
FibroBiologics, Inc. engages in the development and commercialization of cell therapies. It focuses on treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The firm’s product pipeline includes CybroCell, CYMS101, CYWC628, TCB190, and CYTER915. The company was founded by Peter O’Heeron on April 8, 2021 and is headquartered in Houston, TX.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of FBLG is 2.25 USD — it has increased by 10.84% in the past 24 hours. Watch FibroBiologics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange FibroBiologics, Inc. stocks are traded under the ticker FBLG.
FBLG stock has risen by 2.27% compared to the previous week, the month change is a −7.02% fall, over the last year FibroBiologics, Inc. has showed a −92.50% decrease.
We've gathered analysts' opinions on FibroBiologics, Inc. future price: according to them, FBLG price has a max estimate of 16.00 USD and a min estimate of 11.00 USD. Watch FBLG chart and read a more detailed FibroBiologics, Inc. stock forecast: see what analysts think of FibroBiologics, Inc. and suggest that you do with its stocks.
FBLG reached its all-time high on Jan 31, 2024 with the price of 55.00 USD, and its all-time low was 1.08 USD and was reached on Aug 16, 2024. View more price dynamics on FBLG chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
FBLG stock is 13.37% volatile and has beta coefficient of 0.46. Track FibroBiologics, Inc. stock price on the chart and check out the list of the most volatile stocks — is FibroBiologics, Inc. there?
Yes, you can track FibroBiologics, Inc. financials in yearly and quarterly reports right on TradingView.
FibroBiologics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
FBLG earnings for the last quarter are −0.01 USD per share, whereas the estimation was −0.07 USD resulting in a 86.15% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about FibroBiologics, Inc. earnings.
FibroBiologics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
FBLG net income for the last quarter is −500.00 K USD, while the quarter before that showed 898.00 K USD of net income which accounts for −155.68% change. Track more FibroBiologics, Inc. financial stats to get the full picture.
No, FBLG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 10.00 employees. See our rating of the largest employees — is FibroBiologics, Inc. on this list?
Like other stocks, FBLG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FibroBiologics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FibroBiologics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FibroBiologics, Inc. stock shows the buy signal. See more of FibroBiologics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.